The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
暂无分享，去创建一个
R. Scheule | J. Davies | S. Hyde | I. Pringle | D. McCormick | S. Sumner-Jones | D. Gill | G. Mclachlan | A. Baker | P. Tennant | C. Gordon | C. Vrettou | E. Baker | H. Davidson | M. McGovern | Sionagh H. Smith | U. Griesenbach | A. Boyd | T. Higgins | R. Coles | D. Collie | E. Alton | David J. Porteous | J. A. Innes | S. Cheng | Darren J. Shaw | E. W. Alton | J. Innes | D. Porteous
[1] R. Scheule,et al. T4 Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis , 2011, Thorax.
[2] D. Porteous,et al. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung , 2011, Gene Therapy.
[3] R. Scheule,et al. A novel mixing device for the reproducible generation of nonviral gene therapy formulations. , 2010, BioTechniques.
[4] A. Nairn,et al. An immunocytochemical assay to detect human CFTR expression following gene transfer. , 2009, Molecular and cellular probes.
[5] A. Horsley. Lung clearance index in the assessment of airways disease. , 2009, Respiratory medicine.
[6] E. Alton,et al. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. , 2009, Advanced drug delivery reviews.
[7] David N Sheppard,et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression , 2008, Nature Biotechnology.
[8] D. Porteous,et al. Optimizing aerosol gene delivery and expression in the ovine lung. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] P. Gustafsson,et al. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis , 2003, European Respiratory Journal.
[10] W. Colledge,et al. Optimisation of real-time quantitative RT-PCR for the evaluation of non-viral mediated gene transfer to the airways , 2002, Gene Therapy.
[11] J. Clancy,et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. , 2001, Human gene therapy.
[12] S. Durham,et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial , 1999, The Lancet.
[13] M. Knowles,et al. A Double-Blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis. Glaxo Wellcome Research and Development Ltd., London, England , 1998 .
[14] R. Scheule,et al. A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung. , 1997, Human gene therapy.
[15] M. Knowles,et al. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. , 1998, Human gene therapy.
[16] A. Pfeffer,et al. Acute phase response of sheep: changes in the concentrations of ceruloplasmin, fibrinogen, haptoglobin and the major blood cell types associated with pulmonary damage. , 1989, Research in veterinary science.